Fairmount Funds Management’s activist position in Apogee Therapeutics fell from above 5% to 0%, with its securities cancelled in the Merger and converted into $135.11 cash per share. The change matters because Fairmount no longer beneficially owns Apogee securities, while its voting agreement also ended when the transaction closed.
Key Highlights
- Apogee’s merger converted each Fairmount-held common share and non-voting common share into $135.11 in cash.
- Peter Evan Harwin exercised 42,208 vested director stock Options on August 7.
- The voting agreement ended automatically when the merger was completed.
Apogee Therapeutics, Inc. (NASDAQ: APGE) no longer has Fairmount Funds Management LLC as a beneficial owner after the activist investor’s stake fell from above 5% to 0.0%. Fairmount and the associated reporting persons held 0.00 shares following the change. The position reached zero when Apogee’s merger was consummated on September 3, 2026.
Merger Converts Apogee Holdings
Each share of Apogee common stock and non-voting common stock held by the reporting persons immediately before the merger was cancelled and exchanged for $135.11 in cash per share, without interest. Stock options held by the reporting persons were also cancelled and converted into the excess of $135.11 over each option’s exercise price. The transaction left Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P. Peter Evan Harwin and Tomas Kiselak with no beneficial ownership of Apogee securities.
Fairmount Position Reaches Zero
Peter Evan Harwin exercised 42,208 vested director stock options for 42,208 Apogee common shares on August 7, 2026. Under his arrangement with Fairmount Funds Management LLC, any net cash or stock received from those options was to be transferred for the benefit of a Fairmount fund.
Voting Agreement Terminates
The merger automatically ended the voting agreement, which no longer has force or effect. Apogee’s directors, including Kiselak, resigned from the board immediately before the merger became effective.
FAQs
Q: What happened to Fairmount Funds Management’s Apogee Therapeutics stake?
A: Fairmount Funds Management’s activist Apogee stake fell from above 5% to 0.0%. The reporting persons held 0.00 shares after the merger was completed.
Q: How did the Apogee merger affect Fairmount’s holdings?
A: Each covered Apogee share was cancelled and converted into $135.11 in cash per share. Related stock options were also converted based on their exercise prices.
Q: Did Fairmount remain an Apogee shareholder after the merger?
A: No. Fairmount Funds Management and the associated reporting persons no longer beneficially owned Apogee securities after the merger, and the voting agreement ended automatically.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.